The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of tumor biomarkers in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 and preliminary safety in combination with PD-1 checkpoint inhibitor pembrolizumab.
 
Niels Halama
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Merck; Merck KGaA (Inst); Ono Pharmaceutical (Inst); Roche Pharma AG; Roche Pharma AG (Inst)
Speakers' Bureau - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - N/A; University Hospital Heidelberg (Inst)
 
Ulrike Pruefer
No Relationships to Disclose
 
Anna Frömming
Employment - Noxxon Pharma
Stock and Other Ownership Interests - Noxxon Pharma
 
Diana Beyer
Employment - Noxxon Pharma
Stock and Other Ownership Interests - Noxxon Pharma
 
Dirk Eulberg
Employment - Noxxon Pharma
Stock and Other Ownership Interests - Noxxon Pharma
Patents, Royalties, Other Intellectual Property - Noxxon Pharma
 
Jarl Ulf Jungnelius
Employment - Noxxon Pharma
Consulting or Advisory Role - Isofol Medical
 
Aram Mangasarian
Employment - Noxxon Pharma
Leadership - Noxxon Pharma
Stock and Other Ownership Interests - Noxxon Pharma